Covid 19: NITI Aayog in talks with Johnson & Johnson regarding their single-dose vaccine, CONFIRMS Dr VK Paul

Dr VK Paul, Member-Health, NITI Aayog on Friday informed that they are in talks with Johnson & Johnson regarding their single-dose vaccine.

Covid 19: NITI Aayog in talks with Johnson & Johnson regarding their single-dose vaccine, CONFIRMS Dr VK Paul. Image: ANI/Twitter

Dr VK Paul, Member-Health, NITI Aayog on Friday informed that they are in talks with Johnson & Johnson regarding their single-dose vaccine. He said that as per the plan, this vaccine will also be produced in Hyderabad's Bio E.

"We are in talks with Johnson & Johnson regarding their single-dose vaccine. Their vaccine is being produced outside. As per the plan, this vaccine will also be produced in Hyderabad's Bio E: Dr VK Paul, Member-Health, NITI Aayog," ANI tweeted.

TRENDING NOW

See Zee Business Live TV Streaming Below:

Speaking about the Delta A Plus cases, Dr VK Paul said that there are 56 Delta AY.1 (Delta A Plus) cases in 12 states.

There are 56 Delta AY.1 (Delta A Plus) cases in 12 states: Dr VK Paul, Member-Health, Niti Aayog to ANI pic.twitter.com/ewVWX9hL5o

— ANI (@ANI) July 2, 2021

Johnson & Johnson had on Thursday announced that its single-shot Covid-19 vaccine showed promising signs of protection against the Delta variant rapidly spreading across the US and other countries, in a small laboratory study, as per a report by ANI.

According to the company report, the vaccine generated strong, persistent activity against the rapidly spreading Delta variant and other highly prevalent SARS-CoV-2 viral variants. In addition, the data showed that the durability of the immune response lasted through at least eight months, the length of time evaluated to date.

The two preprint study summaries have been submitted to bioRxiv, a non-profit preprint server for the life sciences. The single-dose vaccine, elicited neutralising antibody activity against the Delta variant at an even higher level than what was recently observed for the Beta (B.1.351) variant in South Africa, the report stated, as per ANI.

In the ensemble trial, Johnson & Johnson's vaccine was 85 percent effective against severe/critical disease and demonstrated protection against hospitalisation and death. The vaccine was consistently effective across all regions studied globally, including in South Africa and Brazil, where there was a high prevalence of rapidly emerging Beta and Zeta variants during the study period.

"Today's newly announced studies reinforce the ability of the Johnson & Johnson COVID-19 vaccine to help protect the health of people globally," said Paul Stoffels, MD, Vice Chairman of the Executive Committee and Chief Scientific Officer at Johnson & Johnson, as quoted by ANI.

TAGS:

Johnson & Johnson Niti Aayog